The health giants battle lawsuits linking once popular heartburn drug Zantac to cancer
Board unanimously backs the £5.04 a share offer made by its major shareholder
The global pharmaceutical company revealed that it has the capacity to bottle monkeypox vaccines at its Gqeberha plant
The healthcare company looks to cut debt and grow its medical-devices and consumer-health businesses
The US pharma giant will construct a new building and renovate existing facilities at its Pearl River campus in the US
SA pharmaceutical manufacturer overlooked as department of health awards half of R11bn antiretroviral tender to companies in India
Sale to lenders is necessary to avoid ratcheting up debt payments, and the figure is R35m higher than a competing offer
The pharmaceutical manufacturer said in a trading statement it expects headline earnings per share to increase by at least 20% year on year
Balwani was found guilty of all charges against him for his role in the collapse of the $9bn blood-testing start-up
Remgro and consortium partner MSC have increased their offer to 504p per share for SA’s most valuable hospital group
Brewer joined the board in January 2011 as an independent nonexecutive director, was appointed deputy chair in November 2015 and promoted to chair in April 2018
The pharmaceutical giant is optimistic international procurement agencies will heed clarion calls to procure African-produced vaccines
Equity traders bet the Remgro-led consortium is likely to return with a higher bid
Enhertu extends survival rate of patients compared to standard chemotherapy, data shows
SA is short of 20,000 nurses and 13,000 doctors, says Wharton-Hood
The group’s shares had their best day in seven months on Wednesday after it said all of its divisions were bringing in more revenue than before the pandemic
Consumers will be under pressure and there may be a cost of living crisis, hospital operator says
The outcome is a blow for African governments that had hoped to see newly established facilities used for more than just Covid-19
The group has another new set of financiers, which has given it an extra five months, as well as better terms, to repay the debt
Dissenting shareholders had been elected to the Ascendis’s board last week, raising the prospect of its current lenders calling in their debt
